1. Enayatrad M, Amoori N, Salehiniya H. Epidemiology and trends in breast cancer mortality in Iran. Iran J Public Health. 2015; 44:430-31.
2. Jemal A, Siegel R, Xu J. Cancer statistics. CA Cancer J Clin. 2010; 60: 277-300. [
DOI:10.3322/caac.20073] [
PMID]
3. Banerjee S, Saxena N, Sengupta K,et al. 17alpha-estradiol-induced VEGF-A expression in rat pituitary tumor cells is mediated through ER independent but PI3K-Akt dependent signaling pathway. Biochem Biophys Res Commun. 2003; 300: 209-15. [
DOI:10.1016/S0006-291X(02)02830-9]
4. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nature Reviews Cancer 2009; 9:631-43. [
DOI:10.1038/nrc2713] [
PMID]
5. Chang XZ, Li DQ, Hou YF, et al. Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer. Breast Cancer Res. 2007; 9: 76-85. [
DOI:10.1186/bcr1789] [
PMID] [
PMCID]
6. Shou J, Massarweh S, Osborne CK. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Nat Cancer Inst. 2004; 96: 926 -35. [
DOI:10.1093/jnci/djh166] [
PMID]
7. Rubí v, Luis B, Fabio S. Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (Review). Oncology reports, 2014; 32: 3-15. [
DOI:10.3892/or.2014.3190] [
PMID]
8. Mosselman S, Polman J, Dijkema R.ERβ: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996; 392: 49-53. [
DOI:10.1016/0014-5793(96)00782-X]
9. Dixon D, Couse JF, Korach KS. Disruption of the estrogen receptor gene in mice. Toxicol Pathol. 1997; 25: 518-20. [
DOI:10.1177/019262339702500516] [
PMID]
10. Croce CM. Oncogenes and cancer. N Engl J Med. 2008; 358: 502-11. [
DOI:10.1056/NEJMra072367] [
PMID]
11. Filipowicz W, Bhattacharyya S, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight. Nat Rev Genet. 2008; 9: 102-14. [
DOI:10.1038/nrg2290] [
PMID]
12. Gao FB. Context-dependent functions of specific microRNAs in neuronal development. Neural Develop. 2010; 5: 25-6. [
DOI:10.1186/1749-8104-5-25] [
PMID] [
PMCID]
13. Tyler E, Ghoshal K, Ramaswamy B. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem. 2008; 283: 29897-903. [
DOI:10.1074/jbc.M804612200] [
PMID] [
PMCID]
14. Aamir A, Kevin R, Ginnebaugh1, et al. Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4. BMC Cancer. 2015; 15: 540-51. [
DOI:10.1186/s12885-015-1561-x] [
PMID] [
PMCID]
15. Jiang Z, Zhengzhi Z, Peipei N. Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1expression. Cell Death Disease. 2016; 7: 2454-64. [
DOI:10.1038/cddis.2016.361] [
PMID] [
PMCID]
16. Mingrong L, Keshuo D, Guofeng Z, et al. MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRc. Sci Repotrs. 2015; 5: 8735-45. [
DOI:10.1038/srep08735] [
PMID] [
PMCID]
17. Xiao JM, Zuncai W, Paula D, Ryan, SJ. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004; 5: 607-16. [
DOI:10.1016/j.ccr.2004.05.015] [
PMID]
18. MaI C, Vincent N, Heole'ne F. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res. 2008; 14: 1744-52. [
DOI:10.1158/1078-0432.CCR-07-1833] [
PMID] [
PMCID]
19. Aoife W, Kirti S, Aleksandra B. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. J Pathol. 2014; 233: 368-79 [
DOI:10.1002/path.4363] [
PMID] [
PMCID]
20. Tejal J, Daniel E, Jan St. Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer. Oncotarget. 2016; 7: 57239-57253.3 [
DOI:10.18632/oncotarget.11136] [
PMID] [
PMCID]
21. Daya L, James MW, Nikki H. A systematic evaluation of miRNA:mRNA interactions involved in the migration and invasion of breast cancer cells. J Trans Med. 2013; 11: 57-67. [
DOI:10.1186/1479-5876-11-57] [
PMID] [
PMCID]
22. Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013; 41: 991-5. [
DOI:10.1093/nar/gks1193] [
PMID] [
PMCID]
23. Dweep H. miRWalk - database: prediction of possible miRNA binding sites by "walking" the genes of 3 genomes. J Biomed Inform. 2011; 44: 839-7. [
DOI:10.1016/j.jbi.2011.05.002] [
PMID]
24. Ciafrè SA, Galardi S, Mangiola A. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Communv. 2005; 334: 1351-58. [
DOI:10.1016/j.bbrc.2005.07.030] [
PMID]
25. Pallante P, Visone R, Ferracin M, et al: MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer. 2006; 13: 497-508. [
DOI:10.1677/erc.1.01209] [
PMID]
26. Hanzhen X, Qiulian L, Ruichao C. A multi-step miRNA-mRNA regulatory network construction approach identifies gene signatures associated with endometrioid endometrial carcinoma. Genes. 2016; 7: 1-11. [
DOI:10.3390/genes7060026] [
PMID] [
PMCID]
27. Marta L, Marta B, Luca A, Katia T, Laura M. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood. 2009; 114: 20-26. [
DOI:10.1182/blood-2009-08-237495] [
PMID]
28. Ruiqi M, Chenyu W, Junjian W, Dong W. MiRNA-mRNA Interaction Network in Non-small Cell Lung Cancer. Interdiscip Sci Comput Life Sci. 2016; 8: 209-19. [
DOI:10.1007/s12539-015-0117-8] [
PMID]
29. Shah N1, Jin K, Cruz LA. HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression. Cancer Res. 2013; 73: 5449-58. [
DOI:10.1158/0008-5472.CAN-13-1178] [
PMID] [
PMCID]
30. Daniela L, Verena MC, Eva C. Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance. Gynecol Oncol. 2012; 569-78. [
DOI:10.1016/j.ygyno.2012.09.001] [
PMID]
31. Teh LK, Mohamed NI, Salleh MZ. The risk of recurrence in breast cancer patients treated with tamoxifen: Polymorphisms of CYP2D6 and ABCB1. AAPS J. 2012; 14: 52-59. [
DOI:10.1208/s12248-011-9313-6] [
PMID] [
PMCID]
32. Sylvie RF, Anne DT, Ariane D, Sylvie C. 8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis. PLoS ONE. 2009; 4: 7239-49. [
DOI:10.1371/journal.pone.0007239] [
PMID] [
PMCID]
33. Manavalan TT, Teng Y. Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells. Cancer Lett. 2011; 313: 26-43. [
DOI:10.1016/j.canlet.2011.08.018] [
PMID] [
PMCID]
34. Ward A, Balwierz A, Zhang JD, Ku M. Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene. 2013; 32: 1173-82. [
DOI:10.1038/onc.2012.128] [
PMID]
35. Ikeda K, Kuniko H, Toshihide U, Takashi S. MiR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A. Sci Reports. 2015; 5: 13170-79. [
DOI:10.1038/srep13170] [
PMID] [
PMCID]